Recordati SpAMIL:REC -0.48%94 3-Year ROIIC % is 16.00 as of Dec. 2025, which is 14% above its 10-year median of 14.04. GuruFocus rates MIL:REC with a GF Score™ of 94/100 and a GF Value™ of €60.74 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 941 Drug Manufacturers companies, Recordati SpA ranks better than 67.16% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Recordati SpA's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 16.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Recordati SpA's 3-Year ROIIC % or its related term are showing as below:
MIL:REC's 3-Year ROIIC % is ranked better than 67.16% of 941
companies
in the Drug Manufacturers industry
Industry Median: 3.74
vs MIL:REC: 16.00
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Recordati SpA 3-Year ROIIC % Related Terms
Recordati SpA 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Recordati SpA's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:REC vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Recordati SpA's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Recordati SpA (MIL:REC) has a 3-Year ROIIC % of 16.00 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Recordati SpA and its competitors. This is 14% above median its historical median of 14.04. According to the industry distribution chart, Recordati SpA ranks #309 out of 941 companies in the Drug Manufacturers industry, placing it in the top 32.8%.
Is Recordati SpA's 3-Year ROIIC % too high?
Recordati SpA's current 3-Year ROIIC % of 16.00 is 14% above median its 10-year median of 14.04. The Drug Manufacturers industry median 3-Year ROIIC % is 3.74. Recordati SpA's value of 16.00 is 327.8% above this industry median. Based on the distribution chart, Recordati SpA ranks #309 out of 941 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Recordati SpA has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #309 out of 941 companies for 3-Year ROIIC %. This puts Recordati SpA in the upper half of its industry. The industry median 3-Year ROIIC % is 3.74. Recordati SpA's value of 16.00 is 327.8% above this benchmark. While the company's 10-year median is 14.04 vs. the industry median of 3.74, Recordati SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.74, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current 3-Year ROIIC % of 16.00 is 327.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Recordati SpA and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current 3-Year ROIIC % is 16.00, which is 14% above median its own 10-year median of 14.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.74, compared to a current price of €51.35 — trading 15.5% below its estimated fair value. The current 3-Year ROIIC % is 16.00, which is 14% above median its 10-year median of 14.04 and 327.8% above the Drug Manufacturers industry median of 3.74. Recordati SpA's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current 3-Year ROIIC % is 16.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €51.35 is trading 15.5% below its estimated GF Value™ of €60.74.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
3-Year ROIIC %: 16.00 (14% above median its 10-year median of 14.04)
GF Value™: €60.74 vs. price of €51.35 (15.5% below fair value)
Industry Position: 327.8% above the Drug Manufacturers median (#309 of 941)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
94GF Score
Get the complete analysis for MIL:REC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
